FreshPatents.com Logo
stats FreshPatents Stats
2 views for this patent on FreshPatents.com
2012: 2 views
Updated: October 26 2014
newTOP 200 Companies filing patents this week


    Free Services  

  • MONITOR KEYWORDS
  • Enter keywords & we'll notify you when a new patent matches your request (weekly update).

  • ORGANIZER
  • Save & organize patents so you can view them later.

  • RSS rss
  • Create custom RSS feeds. Track keywords without receiving email.

  • ARCHIVE
  • View the last few months of your Keyword emails.

  • COMPANY DIRECTORY
  • Patents sorted by company.

Follow us on Twitter
twitter icon@FreshPatents

Assay for soluble cd200

last patentdownload pdfdownload imgimage previewnext patent


20120264145 patent thumbnailZoom

Assay for soluble cd200


The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.

Browse recent Trillium Therapeutics Inc. patents - Toronto, CA
Inventors: Reginald M. Gorczynski, Karrie Ka Wai Wong
USPTO Applicaton #: #20120264145 - Class: 435 792 (USPTO) - 10/18/12 - Class 435 
Chemistry: Molecular Biology And Microbiology > Measuring Or Testing Process Involving Enzymes Or Micro-organisms; Composition Or Test Strip Therefore; Processes Of Forming Such Composition Or Test Strip >Involving Antigen-antibody Binding, Specific Binding Protein Assay Or Specific Ligand-receptor Binding Assay >Assay In Which An Enzyme Present Is A Label >Heterogeneous Or Solid Phase Assay System (e.g., Elisa, Etc.)

view organizer monitor keywords


The Patent Description & Claims data below is from USPTO Patent Application 20120264145, Assay for soluble cd200.

last patentpdficondownload pdfimage previewnext patent

FIELD OF THE DISCLOSURE

The disclosure relates to the detection of a soluble form of CD200 found in biological fluids including bodily fluids as well as assays useful for diagnosing and monitoring medical conditions associated with elevated levels of CD200, such as cancer.

BACKGROUND TO THE DISCLOSURE

CD200 is a transmembrane surface protein broadly expressed on a variety of cell types and delivers immunoregulatory signals through binding to receptor (CD200R) expressed on monocytes/myeloid cells and T lymphocytes. Stimulation of CD200R triggers an immune suppression response that is of interest medically in the treatment of autoimmune disorders including rheumatoid arthritis, lupus, asthma and in graft rejection and fetal loss.

Inhibition of the CD200:CD200R cascade inhibits CD200-mediated immune suppression, and thus augments the immune response. Agents that disrupt this interaction accordingly are of interest for the treatment of infectious diseases and cancers, and particularly hematopoietic cancers including leukemia, multiple myeloma and lymphoma as well as melanoma and other cancers (Moreaux et al. Biochem. Biophys. Res. Commun., 2008, 366:117-22). It has been suggested that certain AML tumour cells display an upregulated level of membrane-bound CD200, which can be diagnostic for tumours of this type. Various groups have also reported cellular CD200 overexpression associated with CLL, multiple myeloma, and melanoma (Petermann et al, J. Clin. Invest., 2007, 117(12):3922).

As a membrane-bound protein, cellular CD200 can be detected using cell or tissue-based assays, such as flow cytometry or immunohistochemical staining methods. The use of these techniques to detect cell surface CD200 overexpression in subjects presenting with CLL has been suggested, for instance, in US2005/0129690 to Bowdish et al published Jun. 16, 2005. However, it would be desirable to provide methods that are simple in their format, to facilitate detection of CD200, particularly in subjects afflicted with tumours and other medical conditions in which CD200 is overexpressed relative to healthy subjects.

SUMMARY

OF THE DISCLOSURE

It has now been found that a soluble form of CD200 is detectable in biological fluids including serum. Moreover, the level of CD200 detectable in the serum of subjects presenting with CD200-overexpressing cancers, exceeds the level of CD200 detectable in the serum of control subjects. The present disclosure therefore provides an assay useful to detect soluble CD200 in a sample extracted from a subject, wherein the assay is performed on a sample of biological fluid extracted from the subject. The disclosure further provides a method for identifying a subject having, or at risk for, a medical condition associated with increased CD200 levels and/or associated with cells and/or tumours that over-express CD200, comprising the steps of determining the level of soluble CD200 in the subject, comparing that soluble CD200 level to the soluble CD200 level in a control subject, wherein an elevated soluble CD200 level is diagnostic for a CD200 associated medical condition. The disclosure further provides for the use of the assay to monitor a subject for progression or regression of such a medical condition, such as during and after medical treatment. Also provided by the present disclosure is a method of medical treatment in which a subject is first diagnosed using the assay of the present disclosure, and is then treated, for example, treated to inhibit the CD200:CD200R signalling cascade.

Thus, in one of its aspects, the present disclosure provides a method for determining a level of soluble CD200, the method comprising contacting a biological fluid from a subject with an agent that specifically binds soluble CD200 and detecting the binding thereof to determine the level of soluble CD200.

In another aspect, the disclosure provides a method for identifying a subject having an elevated CD200 level, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated soluble CD200 levels.

In another aspect, the disclosure provides a method for identifying a subject having cells that overexpress cellular CD200, the method comprising the step of assaying biological fluid from the subject to determine the level of soluble CD200, wherein a level above control indicates the presence of said cells.

In a related aspect, the present disclosure provides a method for identifying a subject having or at risk for a medical condition associated with elevated CD200, the method comprising the steps of: a) obtaining a sample of biological fluid from said subject; and b) determining a level of soluble CD200 in said sample, wherein a soluble CD200 level above control indicates said medical condition.

In another aspect, the present disclosure provides a method for monitoring progression in a subject of a medical condition associated with elevated CD200, the method comprising the steps of: a) at a first time point, determining a level of soluble CD200 in a first sample of biological fluid from the subject; and b) comparing the level of soluble CD200 in a subsequent sample of biological fluid taken from said subject at a second time point different from the first time point; wherein a difference in the soluble CD200 levels at the first time point compared to the second time point indicates modulated progression of the condition.

In a further aspect, the present disclosure provides a method of medical treatment useful to control progression of a medical condition associated with overexpression of cellular CD200, comprising the steps of: a) identifying a subject having cells that overexpress cellular CD200 as determined by the assay method of the present disclosure, and b) treating the subject with an agent that inhibits signalling via the CD200:CD200R pathway.

In another aspect, the disclosure provides a method of medical treatment useful to control progression of a medical condition associated with elevated levels of CD200, comprising the steps of: a) identifying a subject having elevated levels of CD200 as determined by the assay method of the present disclosure, and b) treating the subject with an agent that inhibits signalling via the CD200:CD200R pathway.

In still a further aspect of the present disclosure, there is provided an assay useful in the diagnosis of a medical condition associated and/or mediated by cells overexpressing cellular CD200, comprising the steps of: a) obtaining a sample of biological fluid from a subject; b) reacting the sample with an agent that binds soluble CD200; c) detecting bound soluble CD200; and

Download full PDF for full patent description/claims.

Advertise on FreshPatents.com - Rates & Info


You can also Monitor Keywords and Search for tracking patents relating to this Assay for soluble cd200 patent application.
###
monitor keywords



Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Assay for soluble cd200 or other areas of interest.
###


Previous Patent Application:
Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
Next Patent Application:
Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
Industry Class:
Chemistry: molecular biology and microbiology
Thank you for viewing the Assay for soluble cd200 patent info.
- - - Apple patents, Boeing patents, Google patents, IBM patents, Jabil patents, Coca Cola patents, Motorola patents

Results in 0.63577 seconds


Other interesting Freshpatents.com categories:
Qualcomm , Schering-Plough , Schlumberger , Texas Instruments ,

###

Data source: patent applications published in the public domain by the United States Patent and Trademark Office (USPTO). Information published here is for research/educational purposes only. FreshPatents is not affiliated with the USPTO, assignee companies, inventors, law firms or other assignees. Patent applications, documents and images may contain trademarks of the respective companies/authors. FreshPatents is not responsible for the accuracy, validity or otherwise contents of these public document patent application filings. When possible a complete PDF is provided, however, in some cases the presented document/images is an abstract or sampling of the full patent application for display purposes. FreshPatents.com Terms/Support
-g2-0.2146
     SHARE
  
           


stats Patent Info
Application #
US 20120264145 A1
Publish Date
10/18/2012
Document #
File Date
10/31/2014
USPTO Class
Other USPTO Classes
International Class
/
Drawings
0



Follow us on Twitter
twitter icon@FreshPatents